Two analyses show Fycompa (Eisai) effective for Epilepsy
Two new analyses on clinical experience with Fycompa (perampanel), from Eisai, show it is effective and well tolerated in patients with difficult-to-treat partial Epilepsy. The results describe the first real life experiences of perampanel as an adjunctive therapy. In the first study, on 45 patients followed up for at least six months, 47% had a reduction in seizure frequency of at least 50% compared to baseline, and 16% became seizure free. 62% (n=28) of patients experienced adverse events.
In a second study of patients who had intractable epilepsy (52.6% with temporal lobe epilepsy) for an average of 23.7 years, and had previously been treated with an average number of nine AEDs, 21.1% experienced more than a 50% decrease of seizure frequency with perampanel, and a further five patients (26.3%) observed a positive effect, although less than a 50% reduction in seizure frequency. Four patients discontinued treatment. Data was presented at a meeting of the German and Austrian Societies for Epileptology and the Swiss League Against Epilepsy.
Related news and insights
Sorrento Therapeutics, Inc. announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase IIA randomised, placebo-controlled study of intravenous allogenic adipose-derived mesenchymal stromal cells to treat Post COVID 19 "Long Haul" Pulmonary compromise (NCT04992247).
Amryt presents long-term safety and efficacy data from the open-label extension (OLE) of its global Phase III MPOWERED non-inferiority clinical trial that compared Mycapssa (oral octreotide capsules) to long-acting iSRLs (injectable Somatostatin Receptor Ligands) for maintenance of biochemical response in patients with acromegaly.
UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase III BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the first study to evaluate the efficacy and safety of Bimzelx (bimekizumab) in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).